Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Synergistic inhibition of human immunodeficiency virus in vitro by azidothymidine and recombinant alpha A interferon.

Literature DB >> 3471180

Synergistic inhibition of human immunodeficiency virus in vitro by azidothymidine and recombinant alpha A interferon.

K L Hartshorn, M W Vogt, T C Chou, R S Blumberg, R Byington, R T Schooley, M S Hirsch.

Abstract

Both recombinant alpha A interferon and azidothymidine inhibit the replication of human immunodeficiency virus in peripheral blood mononuclear cells. Combinations of recombinant alpha A interferon and azidothymidine at concentrations that are easily achievable in patients synergistically inhibit human immunodeficiency virus in vitro with minimal toxicity. Combinations of antiretroviral compounds that act by different mechanisms may prove useful in the treatment of acquired immunodeficiency syndrome-related disorders.

Entities: Chemical Disease Species

Mesh：

Substances：

Year: 1987 PMID： 3471180 PMCID： PMC174685 DOI： 10.1128/AAC.31.2.168

Source DB: PubMed Journal: Antimicrob Agents Chemother ISSN： 0066-4804 Impact factor: 5.191

18 in total

1. Induction of HTLV-III/LAV from a nonvirus-producing T-cell line: implications for latency.

Authors: T Folks; D M Powell; M M Lightfoote; S Benn; M A Martin; A S Fauci
Journal: Science Date: 1986-02-07 Impact factor: 47.728

2. Promising results halt trial of anti-AIDS drug.

Authors: D M Barnes
Journal: Science Date: 1986-10-03 Impact factor: 47.728

3. Recombinant human interferon alfa-A suppresses HTLV-III replication in vitro.

Authors: D D Ho; K L Hartshorn; T R Rota; C A Andrews; J C Kaplan; R T Schooley; M S Hirsch
Journal: Lancet Date: 1985-03-16 Impact factor: 79.321

4. Inhibition of human T-cell lymphotropic virus type III in vitro by phosphonoformate.

Authors: E G Sandstrom; J C Kaplan; R E Byington; M S Hirsch
Journal: Lancet Date: 1985-06-29 Impact factor: 79.321

5. Synergistic inhibition of human T-cell lymphotropic virus type III replication in vitro by phosphonoformate and recombinant alpha-A interferon.

Authors: K L Hartshorn; E G Sandstrom; D Neumeyer; T J Paradis; T C Chou; R T Schooley; M S Hirsch
Journal: Antimicrob Agents Chemother Date: 1986-07 Impact factor: 5.191

6. Genetic variation in HTLV-III/LAV over time in patients with AIDS or at risk for AIDS.

Authors: B H Hahn; G M Shaw; M E Taylor; R R Redfield; P D Markham; S Z Salahuddin; F Wong-Staal; R C Gallo; E S Parks; W P Parks
Journal: Science Date: 1986-06-20 Impact factor: 47.728

7. Acyclovir enhances the antiviral effect of interferon in chronic hepatitis B.

Authors: S W Schalm; R A Heytink; H R van Buuren; R A de Man
Journal: Lancet Date: 1985-08-17 Impact factor: 79.321

8. Administration of 3'-azido-3'-deoxythymidine, an inhibitor of HTLV-III/LAV replication, to patients with AIDS or AIDS-related complex.

Authors: R Yarchoan; R W Klecker; K J Weinhold; P D Markham; H K Lyerly; D T Durack; E Gelmann; S N Lehrman; R M Blum; D W Barry
Journal: Lancet Date: 1986-03-15 Impact factor: 79.321

9. 3'-Azido-3'-deoxythymidine (BW A509U): an antiviral agent that inhibits the infectivity and cytopathic effect of human T-lymphotropic virus type III/lymphadenopathy-associated virus in vitro.

Authors: H Mitsuya; K J Weinhold; P A Furman; M H St Clair; S N Lehrman; R C Gallo; D Bolognesi; D W Barry; S Broder
Journal: Proc Natl Acad Sci U S A Date: 1985-10 Impact factor: 11.205

10. Detection of human anti-HTLV-III antibodies by indirect immunofluorescence using fixed cells.

Authors: E G Sandstrom; R T Schooley; D D Ho; R Byington; M G Sarngadharan; M E MacLane; M Essex; R C Gallo; M S Hirsch
Journal: Transfusion Date: 1985 Jul-Aug Impact factor: 3.157

48 in total

Review 1. Antiretroviral therapy: strategies beyond single-agent reverse transcriptase inhibition.

Authors: K J Connolly; S M Hammer
Journal: Antimicrob Agents Chemother Date: 1992-03 Impact factor: 5.191

2. Inhibition of human immunodeficiency virus in vitro by combinations of 3'-azido-3'-deoxythymidine and foscarnet.

Authors: R Koshida; L Vrang; G Gilljam; J Harmenberg; B Oberg; B Wahren
Journal: Antimicrob Agents Chemother Date: 1989-05 Impact factor: 5.191

Review 3. Antiviral therapy: current concepts and practices.

Authors: B Bean
Journal: Clin Microbiol Rev Date: 1992-04 Impact factor: 26.132

Review 4. Antiviral therapy for human immunodeficiency virus infections.

Authors: E De Clercq
Journal: Clin Microbiol Rev Date: 1995-04 Impact factor: 26.132

Review 5. Clinical pharmacology of zidovudine and other 2',3'-dideoxynucleoside analogues.

Authors: F Kamali
Journal: Clin Investig Date: 1993-05

Review 6. Interferon-alpha in malignant and viral diseases. A review.

Authors: R T Dorr
Journal: Drugs Date: 1993-02 Impact factor: 9.546

7. Inhibition of human immunodeficiency virus infection by agents that interfere with thiol-disulfide interchange upon virus-receptor interaction.

Authors: H J Ryser; E M Levy; R Mandel; G J DiSciullo
Journal: Proc Natl Acad Sci U S A Date: 1994-05-10 Impact factor: 11.205